Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Health Behavior Change During COVID-19 Pandemic

8 de agosto de 2021 actualizado por: University of Social Sciences and Humanities, Warsaw

Health Behavior Change During COVID-19 Pandemic: the Focus on Handwashing

This study aims at investigating handwashing behavior during COVID-19 pandemic. It was hypothesized that social-cognitive and emotional predictors as well as COVID-19 morbidity and mortality rates within the country would be associated with handwashing behavior in the general population of adults in 14 countries.

Descripción general del estudio

Estado

Terminado

Condiciones

Intervención / Tratamiento

Descripción detallada

This observational study aims at testing the adherence to handwashing guidelines (the World Health Organization, WHO, 2020) at two measurement points, spanning 1 month. Adults from the general population in 14 countries (Poland, Australia, Canada, China, France, Gambia, Germany, Israel, Italy, Malaysia, Portugal, Romania, Singapore, Switzerland) will provide self-report data on handwashing behavior and its social-cognitive predictors (perceived effectiveness of handwashing, risk perception, outcome expectancy, self-efficacy, intention, planning, and action control), anxiety, as well as COVID-19 morbidity and mortality rates within the country.

Tipo de estudio

De observación

Inscripción (Actual)

6079

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

  • Alemania
      • Berlin, Alemania
        • Freie Universität Berlin
  • Australia
      • Melbourne, Australia
        • The University of Melbourne
  • Canadá
      • Fredericton, Canadá
        • University of New Brunswick
  • Francia
      • Bordeaux, Francia
        • University of Bordeaux
  • Gambia
      • Fajara, Gambia
        • London School of Hygiene and Tropical Medicine (in collaboration with MRC Unit The Gambia at LSHTM)
  • Israel
      • Ramat Gan, Israel
        • Bar-Ilan University
  • Italia
      • Padova, Italia
        • University of Padova
  • Malasia
      • Serdang, Malasia
        • Perdana University
  • Polonia
    • Lower Silezia
      • Wroclaw, Lower Silezia, Polonia, 53-328
        • SWPS University of Social Sciences and Humanities
  • Porcelana
      • Beijing, Porcelana
        • Peking University
  • Portugal
      • Lisbon, Portugal
        • University of Lisbon
  • Rumania
      • Cluj-Napoca, Rumania
        • Babes-Bolyai Unversity
  • Singapur
      • Singapore, Singapur
        • Nanyang Technological University
  • Suiza
      • Zürich, Suiza
        • University of Zurich

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

Sí

Géneros elegibles para el estudio

Todos

Método de muestreo

Muestra no probabilística

Población de estudio

Adults in 14 countries are recruited using the snowballing method. Data are collected using an online platform (software: Qualtricts).

Descripción

Inclusion Criteria:

  • adults (from general population) who provided informed consent to participate

Exclusion Criteria:

  • younger than <18 years old

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

Cohortes e Intervenciones

Grupo / Cohorte
Intervención / Tratamiento
Poland
Adults, general population, N = 400
Otro: No intervention
Observational data collection only, accounting for COVID-19 morbidity and mortality levels within each country
Australia
Adults, general population, N = 400
Otro: No intervention
Observational data collection only, accounting for COVID-19 morbidity and mortality levels within each country
Canada
Adults, general population, N = 400
Otro: No intervention
Observational data collection only, accounting for COVID-19 morbidity and mortality levels within each country
China
Adults, general population, N = 400
Otro: No intervention
Observational data collection only, accounting for COVID-19 morbidity and mortality levels within each country
France
Adults, general population, N = 400
Otro: No intervention
Observational data collection only, accounting for COVID-19 morbidity and mortality levels within each country
Gambia
Adults, general population, N = 400
Otro: No intervention
Observational data collection only, accounting for COVID-19 morbidity and mortality levels within each country
Germany
Adults, general population, N = 400
Otro: No intervention
Observational data collection only, accounting for COVID-19 morbidity and mortality levels within each country
Israel
Adults, general population, N = 400
Otro: No intervention
Observational data collection only, accounting for COVID-19 morbidity and mortality levels within each country
Italy
Adults, general population, N = 400
Otro: No intervention
Observational data collection only, accounting for COVID-19 morbidity and mortality levels within each country
Malaysia
Adults, general population, N = 400
Otro: No intervention
Observational data collection only, accounting for COVID-19 morbidity and mortality levels within each country
Portugal
Adults, general population, N = 400
Otro: No intervention
Observational data collection only, accounting for COVID-19 morbidity and mortality levels within each country
Romania
Adults, general population, N = 400
Otro: No intervention
Observational data collection only, accounting for COVID-19 morbidity and mortality levels within each country
Singapore
Adults, general population, N = 400
Otro: No intervention
Observational data collection only, accounting for COVID-19 morbidity and mortality levels within each country
Switzerland
Adults, general population, N = 400
Otro: No intervention
Observational data collection only, accounting for COVID-19 morbidity and mortality levels within each country

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Handwashing adherence
Periodo de tiempo: 1 month
The 12-item self-report measure of adherence to handwashing guidelines across situations (e.g., after visiting public spaces, after touching garbage, etc.) based on the guidelines issued by the World Health Organization and the Centers for Disease Control and Prevention. The responses are provided on a 4-point scale, ranging from 1 (strongly disagree) to 4 (strongly agree). Higher scores indicate better outcomes (the higher level of adherence to handwashing guidelines).
1 month
Frequency of handwashing
Periodo de tiempo: 1 month
The 1-item self-report measure of the frequency of handwashing (for at least 20 seconds, all surfaces of the hands) daily. The responses are provided on a 4-point scale, ranging from 1 (less than once) to 5 (more than 10 times). Higher scores indicate better outcomes (the higher frequency of handwashing).
1 month

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Self-efficacy
Periodo de tiempo: 1 month
4 self-efficacy questionnaire items; mean item score ranging from 1 to 4, higher scores indicate stronger self-efficacy
1 month
Risk perception
Periodo de tiempo: 1 month
3 questionnaire items to assess risk perception; mean item score ranging from 1 to 5, higher scores indicate higher risk perception
1 month
Outcome expectancy
Periodo de tiempo: 1 month
4 items assessing positive (1 item) and negative (1 items) outcome expectancies; mean item scores ranging from 1 to 4, higher scores indicate more positive outcome expectancies
1 month
Intention
Periodo de tiempo: 1 month
2 questionnaire items assessing intention to adhere to handwashing recommendations; mean item scores ranging from 1 to 4, higher scores indicate stronger intention to wash hands (for at least 20 seconds, all surfaces of the hands)
1 month
Planning
Periodo de tiempo: 1 month
2 questionnaire items assessing action planning (1 item) and coping planning (1 item); mean item scores ranging from 1 to 4, higher scores indicate a higher level of self-reported planning
1 month
Action control
Periodo de tiempo: 1 month
3 questionnaire items assessing a facet of action control, namely self-monitoring; mean item scores ranging from 1 to 4, higher scores indicate a higher level of self-reported monitoring of handwashing behavior
1 month
Perceived effectiveness of hand hygiene
Periodo de tiempo: 1 month
1 questionnaire item assessing perceptions of handwashing as an effective means of preventing coronavirus SARS-CoV-2 infection; item scores ranging from 1 to 4, higher scores indicate a higher level of perceived effectiveness of hand hygiene
1 month
Anxiety
Periodo de tiempo: 1 month
7-item self-report scale (Generalized Anxiety Disorder, GAD-7) scale to assess anxiety symptoms; mean item scores ranging from 1 to 4, higher scores indicate a higher level of generalized anxiety
1 month
Country-level COVID-19 morbidity and mortality rates
Periodo de tiempo: 60 days
The daily cumulative numbers for COVID-19 morbidity and mortality in the study countries. Published daily as the Situation Report by World Health Organization, starting on 21 January 2020. Higher numbers indicate the higher cumulative COVID-19 morbidity and mortality rates in the country.
60 days

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

University of Social Sciences and Humanities, Warsaw

Investigadores

  • Investigador principal: Aleksandra Luszczynska, PhD, SWPS University of Social Sciences and Humanities

Publicaciones y enlaces útiles

La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.

Publicaciones Generales

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

25 de marzo de 2020

Finalización primaria (Actual)

24 de septiembre de 2020

Finalización del estudio (Actual)

24 de septiembre de 2020

Fechas de registro del estudio

Enviado por primera vez

28 de abril de 2020

Primero enviado que cumplió con los criterios de control de calidad

28 de abril de 2020

Publicado por primera vez (Actual)

29 de abril de 2020

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

10 de agosto de 2021

Última actualización enviada que cumplió con los criterios de control de calidad

8 de agosto de 2021

Última verificación

1 de agosto de 2020

Más información

Términos relacionados con este estudio

Palabras clave

Términos MeSH relevantes adicionales

Otros números de identificación del estudio

  • 3228-1BPSYPSBEH-30

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

INDECISO

Descripción del plan IPD

The lead researchers in 14 countries will have full access to data collected across the countries.

In line with the Consortium Agreement (v2, 16th Jul 2020) data will be openly available under following conditions:

De-identified individual participant data that underline the results reported in publications; individual-level aggregated data (e.g., sum scores for scales) used for main analyses in respective publications; available following the publication, no end date of availability; available for analyses that are conducted to achieve aims in the approved proposal.

Due to local regulations, there are exceptions in terms of data sharing rules (stated above):

  • AUSTRALIA: Data from Australia will be available for 5 years after collection.
  • GERMANY, SWITZERLAND: Instead of individual-level sum scores, variance-covariance matrices will be shared.
  • MALAYSIA: Data will not be shared.

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Ensayos clínicos sobre Comportamiento de salud

Ensayos clínicos sobre No intervention

Buscar ensayos similares

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

CROs by country

CROs in Lithuania

Condiciones

Enfermedades Raras

Intervenciones de drogas

Suplementos dietéticos

Patrocinador / Colaboradores

Localizaciones

Suscribir